Conference: Cell and Gene Therapies/ ATMPs - Quality and Safety

26/27 November 2024

Objectives

This meeting is aimed at manufacturers and developers of cells, tissues, cell- and tissue-based products or ATMPs and deals with microbiological and analytical quality requirements, suitable methods and test systems and their implementation and validation. Representatives from authorities and colleagues from small-scale and industrial manufacturing and academic institutions will explain the current regulatory requirements and report on their experiences during inspections and implementation in the company.

Background

Modern regenerative medicine systems such as cells and tissues or ATMPs (gene therapeutics, somatic cell-based products and tissue-based products) represent an innovative group of medicinal products that is becoming increasingly important. With the entry into force of several regulatory directives, e.g. the European Directive EC 1394/2007 for ATMPs, such products have been classified as medicinal products and as such must comply with EU requirements for medicinal products. Although the biopharmaceutical industry has significantly intensified its activities in this area, many of these products are developed and manufactured at universities, hospitals and in small and medium-sized enterprises. These university or medical roots lead to special challenges for the respective institutions as well as for the regulatory authorities in meeting compliance requirements for quality, safety and GMP aspects and approval. The frequently given manufacturing conditions also contribute to this, e.g. the open manipulation of cells and tissues necessary for obtaining such products on a medical-surgical level, or the short shelf life of the obtained end product. And potentially there are always conflicts when it comes to the relevance of different guidelines, e.g. when an Annex 1, or an Annex 2 or a WHO Guideline does not harmonise with the ATMP Guideline.

But also rapid tests and analyses are a challenge for such products with a short shelf life in terms of

  • Comparability with Compendial Methods
  • Sensitivity and Robustness
  • Suitability Testing and Validation
  • Variability

Target Audience

This conference is of interest to professionals from

  • Biotechnological & Biopharmaceutical Companies
  • Contract Service Laboratories
  • Academic Research Institutions and Organizations
  • Government Agencies
  • Cell Culture Collections
  • Supplier Detection Systems

with responsibilities in

  • Manufacturing
  • Quality Assurance
  • Quality Control
  • Regulatory Affairs
  • Research & Development
  • Process Development
  • Validation


Registration

 

Programme

Key Note on 26 November: The Promise and Challenges of In Vitro and In Silico Models in Drug Development
Dr Julia Schüler, Charles River Laboratories
The presentation will highlight important developments in the drug development technology landscape influenced by the concept of 3R and the evolving legal landscape. General characteristics of the different applications, their translational relevance as well as adoption drivers will be discussed. Case studies from oncology drug development will help to elucidate these trends and their impact on future processes.

Key Note on 27 November: Trends & Challenges for the Development & Testing of Biotech Drug Products
Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO), ten23 health

Efficient Microbial Control Concepts for ATMPs
Dr Holger Kavermann, Roche

Critical Quality Attributes of AAV based GT products
Dr Roland Pach, Roche

A ddPCR Method for Multiplex Determination of AAV Genome and Vector Titer
Dr Christian Schiller, Eurofins

Microbial Control for ATMP Facilities
Cecilia Pierobon, STERIS

Key Insights about CAR-T Therapy from Concept to Clinic
Dr Daniela Rozkova, SCTbio

Digital PCR Applications for Cell and Gene Therapy – Standardization for a High-Quality Process Development
Dr Andreas Hecker, QIAGEN

European Pharmacopeia Perspective
Dr Solène Le Maux, EDQM

Spilling the Tea on a Robust CCS for ATMPs
Marsha Steed, Steed MicroBio

Test for Microbial Purity on MCB
Christine Weiß, Labor LS

What is the Value of Design-of-Experiment Approaches in the Development of Cell-based Potency Assays?
Dr Johannes Solzin, Boehringer Ingelheim

Implementation of ICH Q14 and USP <1220>: A challenge in the Highly Competitive mRNA Vaccine Field
Dr Isabelle Moineau, Aktehom
Dr Marc Francois Heude, Sanofi

Continuous Microbial Monitoring in ATMP Facilities in Compliance with the New EU GMP Annex 1
Dr Emad Albarouki, Particle Measuring System (PSM)

x